Graft Embolization versus Nephrectomy in Patients with Graft Intolerance and Infection: A Retrospective Cohort Study

移植肾栓塞术与肾切除术治疗移植肾不耐受和感染患者的疗效比较:一项回顾性队列研究

阅读:1

Abstract

INTRODUCTION: After graft failure, kidney transplant recipients may develop immunological intolerance to the allograft left in situ. In such cases, surgical removal of the allograft is usually performed, but is associated with substantial morbidity and mortality. A less invasive option is percutaneous embolization of the renal artery. Here, we describe our clinical experience with embolization and report observed differences with graft nephrectomy. METHODS: In this retrospective, single-center study, we included kidney transplant recipients who underwent either graft nephrectomy or embolization between 2018 and 2024. Patients with indication "gain of space" were excluded. We reported on major post-procedural complications within three months (Clavien Dindo score 3-4), post-embolization syndrome, blood transfusions, length of hospitalization and readmissions, and mortality. RESULTS: We included 13 embolizations and 32 graft nephrectomies. Major post-procedural complications occurred in 23% after embolization versus 41% after nephrectomy (p = 0.32). Length of hospitalization was shorter after embolization compared to nephrectomy (median 1 vs. 5 days, p = 0.001). Post-embolization syndrome occurred in 9 of 13 patients (69%) and was managed conservatively. One patient with recent graft infections required a subsequent nephrectomy for infected necrosis after embolization. Another patient with residual blood flow after embolization required a nephrectomy for persisting hematuria. Two patients with pre-existing sepsis and bacteriemia died after embolization. CONCLUSIONS: Embolization results in shorter length of hospitalization and is likely associated with a reduced incidence of procedure-related major complications as compared to nephrectomy. Pre-existing sepsis is a risk factor for adverse outcomes after embolization, and recent graft infections should be considered a contra-indication.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。